Treating polyarteritis nodosa: Current state of the art

Clinical and Experimental Rheumatology

Volumn 29, Issue 1 SUPPL. 64, 2011, Pages

  De Menthon, M ^a   Mahr, Alfred ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Cyclophosphamide; Hepatitis B; Polyarteritis nodosa; Therapy; Vasculitis

Indexed keywords

ALPHA2 INTERFERON; AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; LAMIVUDINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; VIDARABINE; COLCHICINE; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE;

ADJUVANT THERAPY; ANTIVIRAL THERAPY; CHURG STRAUSS SYNDROME; CORTICOSTEROID THERAPY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HEPATITIS B; HEPATITIS B VIRUS ASSOCIATED POLYARTERITIS NODOSA; HEPATITIS C; HUMAN; INCIDENCE; MICROSCOPIC POLYANGIITIS; MORTALITY; NOMENCLATURE; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN POLYARTERITIS NODOSA; SURVIVAL RATE; WEGENER GRANULOMATOSIS; ACUTE DRUG ADMINISTRATION; DISEASE CLASSIFICATION; HEPATITIS B VIRUS; IDIOPATHIC DISEASE; MEDICAL EXPERT; NONHUMAN; PLASMA EXCHANGE; PRACTICE GUIDELINE; PREVALENCE; RETROSPECTIVE STUDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 79960398044     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. KUSSMAUL A, MAIER K: Über eine nicht bisher beschriebene eigentümliche Arterienerkrankung (Periarteritis Nodosa) die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1866; 1: 484-518.
2. WEGENER F: Über generalisierte, septische Gefässerkrankungen. Verh Dtsch Pathol Ges 1936; 29: 202-10.
3. CHURG J, STRAUSS L: Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27: 277-301.
4. KAWASAKI T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children (in Japanese). Arerugi 1967; 16: 178-222.
5. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
6. BASU N, WATTS R, BAJEMA I et al.: EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69: 1744-50.
7. LIGHTFOOT RW JR, MICHEL BA, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33: 1088-93.
8. HENEGAR C, PAGNOUX C, PUECHAL X et al.: A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum 2008; 58: 1528-38.
9. WATTS R, LANE S, HANSLIK T et al.: Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-7.
10. GOCKE DJ, HSU K, MORGAN C, BOMBARDIERI S, LOCKSHIN M, CHRISTIAN CL: Association between polyarteritis and Australia antigen. Lancet 1970; 2: 1149-53.
11. TRÉPO C. THIVOLET J: Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970; 19: 410-1.
12. SAADOUN D, TERRIER B, SEMOUN O, SENE D, MAISONOBE T, MUSSET L et al.: Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) (in press).
13. LINDBERG K: Ein Beitrag zur Kenntnis der Periarteritis Nodosa. Acta Scand Med 1931; 76: 183-225.
14. ISHIGURO N, KAWASHIMA M: Cutaneous polyarteritis nodosa: a report of 16 cases with clinical and histopathological analysis and a review of the published work. J Dermatol 2010; 37: 85-93.
15. DIAZ-PEREZ JL, DE LAGRAN ZM, DIAZ-RAMON JL, WINKELMANN RK: Cutaneous polyarteritis nodosa. Semin Cutan Med Surg 2007; 26: 77-86.
16. MORGAN AJ, SCHWARTZ RA: Cutaneous polyarteritis nodosa: a comprehensive review. Int J Dermatol 2010; 49: 750-6.
17. HAUGEBERG G, BIE R, BENDVOLD A, LARSEN AS, JOHNSEN V: Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17: 364-8.
18. MAHR A, GUILLEVIN L, POISSONNET M, AYME S: Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51: 92-9.
19. MOHAMMAD AJ, JACOBSSON LT, MAHR AD, STURFELT G, SEGELMARK M: Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46: 1329-37.
20. ORMEROD AS, COOK MC: Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 2008; 38: 816-23.
21. REINHOLD-KELLER E, ZEIDLER A, GUTFLEISCH J, PETER HH, RASPE HH, GROSS WL: Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000; 39: 1396-402.
22. EL-RESHAID K, KAPOOR MM, EL-RESHAID W, MADDA JP, VARRO J: The spectrum of renal disease associated with microscopic polyangiitis and classic polyarteritis nodosa in Kuwait. Nephrol Dial Transplant 1997; 12: 1874-82.
23. GONZALEZ-GAY MA, GARCIA-PORRUA C, GUERRERO J, RODRIGUEZ-LEDO P, LLORCA J: The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49: 388-93.
24. MOHAMMAD AJ, JACOBSSON LT, WESTMAN KW, STURFELT G, SEGELMARK M: Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009; 48: 1560-5.
25. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al.: No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford) 2002; 41: 540-9.
26. WATTS RA, LANE SE, BENTHAM G, SCOTT DG: Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43: 414-9.
27. PAGNOUX C, SEROR R, HENEGAR C et al.: Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62: 616-26.
28. DAOUD MS, HUTTON KP, GIBSON LE: Cutaneous periarteritis nodosa: a clinico-pathological study of 79 cases. Br J Dermatol 1991; 136: 706-13.
29. GUILLEVIN L, LHOTE F, GAYRAUD M et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996: 75: 17-28.
30. GUILLEVIN L, PAGNOUX C, SEROR R, MAHR A, MOUTHON L, LE TOUMELIN P: The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90: 19-27.
31. FORTIN PR, LARSON MG, WAITERS AK, YEADON CA, CHOQUETTE D, ESDAILE JM: Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group - a review of 45 cases. J Rheumatol 1995; 22: 78-84.
32. FROHNERT PP, SHEPS SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43: 8-14.
33. LEIB ES, RESTIVO C, PAULUS HE: Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67: 941-7.
34. SACK M, CASSIDY JT, BOLE GG: Prognostic factors in polyarteritis. J Rheumatol 1975; 2: 411-20.
35. FAUCI AS, KATZ P, HAYNES BF, WOLFF SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-8.
36. COHEN RD, CONN DL, ILSTRUP DM: Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 1980; 55: 146-55.
37. FAUCI AS. DOPPMAN JL. WOLFF SM: Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med 1978; 64: 890-4.
38. GAYRAUD M, GUILLEVIN L, LE TOUMELIN P et al.: Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-75.
39. GUILLEVIN L, JARROUSSE B, LOK C et al.: Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991; 18: 567-74.
40. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7.
41. GAYRAUD M, GUILLEVIN L, COHEN P et al.: Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-7.
42. GUILLEVIN L, COHEN P, MAHR A et al.: Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49: 93-100.
43. GUILLEVIN L, FAIN O, LHOTE F et al.: Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 1992; 35: 208-15.
44. GUILLEVIN L, LHOTE F, COHEN P et al.: Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and ChurgStrauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-45.
45. RIBI C, COHEN P, PAGNOUX C et al.: Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62: 1186-97.
46. RIBEIRO E, CRESSEND T, DUFFAU P et al.: Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare. Case Reports in Medicine, vol. 2009, Article ID 738293, 3 pages, 2009.
47. GUILLEVIN L, LHOTE F, LEON A, FAUVELLE F, VIVITSKI L, TREPO C: Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993; 20: 289-98.
48. GUILLEVIN L, LHOTE F, SAUVAGET F et al.: Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 334-7.
49. GUILLEVIN L, MAHR A, COHEN P et al.: Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51: 482-7.
50. GUILLEVIN L, MAHR A, CALLARD P et al.: Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-22.
51. VEGA GUTIERREZ J, RODRIGUEZ PRIETO MA, GARCIA RUIZ JM: Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 2007; 21: 570-1.